Ultragenyx announced a workforce reduction of about 130 roles, roughly 10% of its headcount, as part of a restructuring aimed at reaching profitability in 2027. The move follows disappointing clinical outcomes in osteogenesis imperfecta trials and ongoing manufacturing questions causing FDA delays for its gene therapy UX111 for Sanfilippo syndrome type A. The company said it will align resources to its highest‑value programs while responding to FDA requests for additional manufacturing documentation. Analysts cited uncertainty over regulatory timelines for gene therapies and the potential impact on near‑term revenue and investor sentiment.